The Dual-Target Strategy in Rheumatoid Arthritis

As treatments for psoriatic arthritis (PsA) emerge, a clinical trial comparing the Janus kinase (JAK) inhibitor upadacitinib and the tumor necrosis fac­tor (TNF) inhibitor adalimumab provided some new insights. Published earlier this year in The New England Journal of Medi­cine, the SELECT-PsA 1, double-blind, phase 3 trial found that a 30 mg dose of upadacitinib... [Read More]

Source: The Rheumatologist - October 14, 2021 Category: Rheumatology Authors: Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD Tags: Conditions Patient Perspective Rheumatoid Arthritis Disease Activity Score (DAS) patient centeredness shared decision making Speak Out Rheumatology Treat-to-Target Source Type: research